Word

JULVIO

Status

Dead

Status Code

606

Status Date

Monday, November 2, 2020

Serial Number

88149322

Mark Type

4000

Filing Date

Wednesday, October 10, 2018

Published for Opposition

Tuesday, August 6, 2019

Abandoned Date

Monday, November 2, 2020

Trademark Owner History

Mezzion Pharma Co., Ltd. - Owner At Publication

Classifications

5 Pharmaceutical preparations for the treatment of cardiac disease, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation; medicinal preparations for cardiac disease, namely, single ventricle heart disease (SVHD); pharmaceuticals, namely, drugs for the treatment of cardiac disease, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation

41 Educational services, namely, lectures, seminars, training and classes in the field of pharmaceuticals, medicine, health, wellbeing, and cardiac issues, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation; education, namely, lectures, seminars, classes and training in the use of pharmaceuticals for cardiac and other health issues

42 Medical and pharmaceutical research for the treatment of cardiac disease, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation and development services; scientific and technological research services related thereto, namely, scientific research services for the treatment of cardiac disease, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation; medical testing and screening services, namely, providing medical testing services and information in the field of the treatment of cardiac disease, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation; conducting clinical trials for others

44 Medical testing and screening services, namely, medical diagnostic testing services and medical screening the treatment of cardiac disease, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation

Trademark Events

Nov 2, 2020

Abandonment Notice E-Mailed - No Use Statement Filed

Nov 2, 2020

Abandonment - No Use Statement Filed

Apr 3, 2020

Notice Of Approval Of Extension Request E-Mailed

Apr 1, 2020

Extension 1 Granted

Apr 1, 2020

Extension 1 Filed

Apr 1, 2020

Teas Extension Received

Oct 1, 2019

Noa E-Mailed - Sou Required From Applicant

Aug 6, 2019

Official Gazette Publication Confirmation E-Mailed

Aug 6, 2019

Published For Opposition

Jul 17, 2019

Notification Of Notice Of Publication E-Mailed

Jul 1, 2019

Approved For Pub - Principal Register

Jun 21, 2019

Teas/Email Correspondence Entered

Jun 21, 2019

Correspondence Received In Law Office

Jun 19, 2019

Assigned To Lie

Jun 14, 2019

Teas Response To Office Action Received

Jan 24, 2019

Notification Of Non-Final Action E-Mailed

Jan 24, 2019

Non-Final Action E-Mailed

Jan 24, 2019

Non-Final Action Written

Jan 22, 2019

Assigned To Examiner

Oct 19, 2018

New Application Office Supplied Data Entered In Tram

Oct 13, 2018

New Application Entered In Tram